Cibc Asset Management Inc Fate Therapeutics Inc Transaction History

Cibc Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 06, 2022	SELL	$29.67 - $60.28 $114,763 - $233,163	-3,868 Closed	0 $0
Q4 2021 Feb 08, 2022	BUY	$47.84 - $64.34 $4,736 - $6,369	99 Added 2.63%	3,868 $226,000
Q3 2021 Nov 09, 2021	BUY	$59.27 - $95.73 $31,827 - $51,407	537 Added 16.62%	3,769 $223,000
Q1 2021 May 14, 2021	BUY	$72.16 - $117.4 $5,556 - $9,039	77 Added 2.44%	3,232 $266,000
Q4 2020 Feb 03, 2021	BUY	$38.09 - $100.95 $120,173 - $318,497	3,155 New	3,155 $287,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.